{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-281817","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2026-06-25T11:10:11+00:00","discovered_at":"2026-06-25T11:15:00.247209+00:00","generated_at":"2026-06-25T11:15:24.477166+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kymera completes enrollment in Phase 2b KT-621 AD trial; topline data accelerated to year-end 2026","bullets":["Enrollment in BROADEN2 completed nearly six months ahead of schedule; topline data now expected by year-end 2026.","Phase 3 trials in atopic dermatitis planned to initiate by mid-2027, subject to regulatory discussions.","BROADEN2 is a randomized, double-blind, placebo-controlled trial in ~200 patients ages 12-75 over 16 weeks.","KT-621 also in BREADTH Phase 2b asthma trial with data expected in late 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-281817","json":"https://secwatch.observer/filing/0001193125-26-281817.json","markdown":"https://secwatch.observer/filing/0001193125-26-281817.md","text":"https://secwatch.observer/filing/0001193125-26-281817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/0001193125-26-281817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T11:15:24.477166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}